Iovance Biotherapeutics I...

3.50
0.25 (7.69%)
At close: Apr 02, 2025, 11:24 AM

Iovance Biotherapeutics Statistics

Share Statistics

Iovance Biotherapeutics has 327.88M shares outstanding. The number of shares has increased by 17.17% in one year.

Shares Outstanding 327.88M
Shares Change (YoY) 17.17%
Shares Change (QoQ) 7.58%
Owned by Institutions (%) 79.63%
Shares Floating 265.54M
Failed to Deliver (FTD) Shares 28.77K
FTD / Avg. Volume 0.3%

Short Selling Information

The latest short interest is 61.98M, so 20.34% of the outstanding shares have been sold short.

Short Interest 61.98M
Short % of Shares Out 20.34%
Short % of Float 25.09%
Short Ratio (days to cover) 7.04

Valuation Ratios

The PE ratio is -5.76 and the forward PE ratio is -7.31. Iovance Biotherapeutics's PEG ratio is 0.18.

PE Ratio -5.76
Forward PE -7.31
PS Ratio 13.07
Forward PS 0.7
PB Ratio 3.02
P/FCF Ratio -5.89
PEG Ratio 0.18
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Iovance Biotherapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.74, with a Debt / Equity ratio of 0.08.

Current Ratio 3.74
Quick Ratio 3.31
Debt / Equity 0.08
Debt / EBITDA -0.14
Debt / FCF -0.16
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $195.79K
Profits Per Employee $-444.13K
Employee Count 838
Asset Turnover 0.18
Inventory Turnover 2.41

Taxes

Income Tax -2.83M
Effective Tax Rate 0.75%

Stock Price Statistics

The stock price has increased by -76.4% in the last 52 weeks. The beta is 0.93, so Iovance Biotherapeutics's price volatility has been higher than the market average.

Beta 0.93
52-Week Price Change -76.4%
50-Day Moving Average 4.79
200-Day Moving Average 8.01
Relative Strength Index (RSI) 28.35
Average Volume (20 Days) 9.62M

Income Statement

In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M and earned -372.18M in profits. Earnings per share was -1.28.

Revenue 164.07M
Gross Profit 40.08M
Operating Income -395.28M
Net Income -372.18M
EBITDA -395.28M
EBIT -395.28M
Earnings Per Share (EPS) -1.28
Full Income Statement

Balance Sheet

The company has 115.69M in cash and 57.26M in debt, giving a net cash position of 58.43M.

Cash & Cash Equivalents 115.69M
Total Debt 57.26M
Net Cash 58.43M
Retained Earnings -2.38B
Total Assets 910.43M
Working Capital 334.68M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -352.98M and capital expenditures -11.07M, giving a free cash flow of -364.05M.

Operating Cash Flow -352.98M
Capital Expenditures -11.07M
Free Cash Flow -364.05M
FCF Per Share -1.26
Full Cash Flow Statement

Margins

Gross margin is 24.43%, with operating and profit margins of -240.92% and -226.84%.

Gross Margin 24.43%
Operating Margin -240.92%
Pretax Margin -228.56%
Profit Margin -226.84%
EBITDA Margin -240.92%
EBIT Margin -240.92%
FCF Margin -221.88%

Dividends & Yields

IOVA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for IOVA is $19.5, which is 500% higher than the current price. The consensus rating is "Buy".

Price Target $19.5
Price Target Difference 500%
Analyst Consensus Buy
Analyst Count 8
Stock Forecasts

Stock Splits

The last stock split was on Sep 26, 2013. It was a backward split with a ratio of 1:100.

Last Split Date Sep 26, 2013
Split Type backward
Split Ratio 1:100

Scores

Altman Z-Score -1.2
Piotroski F-Score 4